Method for treatment of patients with locally spread squamous cell larynx cancer

FIELD: medicine, oncology.

SUBSTANCE: method involves carrying out the preliminary catheterization of larynx artery and the following intra-arterial chemotherapy by administration of cisplatin as 6 h infusion of 80-100 ml of 0.0025% solution from 1-st to 4-th day of treatment in the total dose 100 mg/m2, 5-fluorouracil as 3 h infusion of 20 ml of 5% solution from 5-th to 7-th day of treatment in the total dose 3 g. After termination of chemotherapy in 2-3 weeks after arresting adverse reactions in tumor regression above 50% the larynx resection is carried out and in regression less 50% - laryngoectomy. In 3-4 weeks after surgery operation the distance radiation therapy is carried out in a single irradiation dose 2.0 Gr in irradiation regimen 5 times per a week and in the total dose 40-46 Gr in laryngoectomy and 60-66 Gr in organ-retaining surgery operation depending on the stage of the primary process. Method provides the functional rehabilitation of patients and decreasing expression and amount of total complications of complex therapy based on step-by-step carrying out the treatment. Invention can be used in treatment of patients with locally spread squamous larynx cancer.

EFFECT: improved method of treatment.

1 ex

 

A method of treating patients with locally advanced squamous cell cancer of the larynx.

The invention relates to medicine, in particular to Oncology, and relates to methods of treating patients with locally advanced squamous cell cancer of the larynx.

Known methods of treating patients with locally advanced squamous cell cancer of the larynx, which includes radiation therapy and surgery in various combinations (Tumors of the head and neck, Aeacs, M, Medicine, s-379, 1997), as well as combining systemic chemotherapy with radiation therapy or surgery (G. B. Adilbaev et al. Proceedings of the 3rd Congress of oncologists and radiologists of the CIS, Minsk, p.4, 2004).

The closest achieved a positive result (the prototype) is a method of treating patients with locally advanced squamous cell cancer of the larynx, which is to assign 2 courses of chemotherapy by intravenous cisplatin and 5-fluorouracil in conducting the second stage of the combined treatment of surgical intervention (proceedings of the 3rd Congress of oncologists and radiologists of the CIS. Long-term results of treatment of patients with laryngeal cancer T-T M, N.m.amiraliev and others, the Ministry of health of Republic of Belarus. Minsk. 25-28 may 2004, part 2. ODO "Topic" 2004, 5). The disadvantage of this method is the low efficacy and high toxicity.

The authors offer a new the th effective method of treating patients with locally advanced squamous cell cancer of the larynx, which consists in stage-by-stage treatment: chemotherapy, surgery and radiation therapy followed by surgical rehabilitation.

The technical result of the invention is to increase the effectiveness of treatment, functional rehabilitation and improvement of patients ' quality of life.

The technical result is achieved by the fact that at the first stage of complex treatment course neoadjuvant intra-arterial regional chemotherapy: cisplatin in the form of a 6-hour infusion of 80-100 ml 0,0025% solution with 1 St to 4-th day of treatment (total dose 100 mg/m2), 5-fluorouracil as 3-hour infusion of 20 ml of 5% solution of 5-th and 7-th day of treatment (total dose 3 g), in the second stage of complex treatment of simultaneous surgery on routes of lymphatic drainage and primary tumor site. 3-4 weeks after complete surgical intervention in patients conduct remote radiation therapy.

The proposed method of treatment is as follows

The patient undergo chemotherapy, then surgery, then the rate of postoperative radiation therapy. Produce catheterization laryngeal artery catheters are retrograde through the upper thyroid artery that is distal to the bandage. Drugs injected intraarterially through the catheter. And what the fusion is carried out with the help of a dispenser of drugs "Lineout", GCal-MARX-STADT. Scheme of chemotherapy includes two drug: cisplatin in the form of a 6-hour infusion of 80-100 ml 0,0025% solution with 1 to 4-day treatment with a total dose of 100 mg/m2With 5-fluorouracil in the form of a 3-hour infusion of 20 ml of 5% solution of 5-th and 7-day treatment with a total dose of 3 g After treatment is 2-3 weeks after edema adverse reactions patients spend combined surgery on InfoPath neck and the base of the hearth. When tumor regression over 50% perform resection of the larynx in various modifications, when the regression is less than 50% of the laryngectomy. 3-4 weeks after complete surgical intervention in patients conduct remote radiation therapy. Perform irradiation with gamma-therapeutic setting "Rocus-AM, a single dose is 2.0 Gy, radiation treatment 5 times a week, total dose reaches 40-46 Gy when laryngectomy, with conservative surgical intervention dose to the larynx is 60-66 Gy depending on the stage of the primary process. In 3-6 months, if necessary, is the closure of the laryngo - and tracheostomy.

The essence of the invention lies in the fact that in the preoperative period undergo neoadjuvant intra-arterial regional chemotherapy: cisplatin in the form of a 6-hour infusion of 80-100 ml 0,0025% solution with 1 St to 4-th day laciniosa a dose of 100 mg/m 2With 5-fluorouracil in the form of a 3-hour infusion of 20 ml of 5% solution of 5-th and 7-day treatment with a total dose of 3 g Catheterization laryngeal artery conduct retrograde access via the superior thyroid artery.

Clinical example

Patient Samsonov A. C., 46 years old, was treated in the Department of head and neck tumors of September, 2003 Diagnosis: cancer of the larynx 3 STTs N0M0. DG No. 1159 from 16.09.03. squamous cell carcinoma with a tendency to keratinization. Objectively before treatment the patient was determined ulcero-infiltrative form of growth of the tumor occupying the entire left a voice crease with the transition to podskladochny space, there was paresis of the larynx to the left. 30.9.03. operation performed: catheterization of the superior thyroid artery to the left. 1-6.10.03. a course of intra-arterial regional chemotherapy under the above scheme. After the chemotherapy in the survey was determined residual tumor mixed growth form, occupying part of the left vocal fold. Effects after chemotherapy is over 50%. 27.12.03 bolinao operation was performed in the volume: front-side resection of the larynx to the left. DG No. 3810 from 5.12.03. squamous cell carcinoma, therapeutic pathomorphosis 4 tbsp. Wound healed by first intention.

22.12.03.-4.02.04. patients received a course of postoperative gamma-therapy, single focal dose is left Gr 2, 5 times a week, total - 66 Gr.

8.06.04. the patient was performed plastic surgery laryngectomy with reinforcement of the skin flap autoreport. The wound healed by first intention. The recovered voice and barrier functions of the larynx.

The proposed method only received treatment 3 patients. At stage 1, all patients received a course of regional chemotherapy: cisplatin in the form of a 6-hour infusion of 80-100 ml 0,0025% solution with 1 to 4-day treatment with a total dose of 100 mg/m2With 5-fluorouracil in the form of a 3-hour infusion of 20 ml of 5% solution of 5-th and 7-day treatment with a total dose of 3, all patients were catheterized laryngeal artery. In all 3 cases after 1 year regional chemotherapy achieved tumor regression over 50%.

In respect of regional metastases in one case (T3N1M0) was awarded a partial regression of metastatic lymph node. It should be noted that in this case was showed complete regression of the primary tumor.

Therapeutic pathomorphosis (all patients operated) amounted to: Art. IV - 2 patients, Art. II - 1 patient. Complications RPT: 1 case when conducting RPT through laryngeal artery developed necrosis of soft tissues in the area of blood supply to last after the introduction of 4 gr. 5-FU. Subsequently the patient was performed resection of the larynx. After dose reduction FU to 3 gr complications of this nature we do not UGT is ecoli.

Surgical treatment

Primary focus: in 2 cases after conducting RPT managed to perform resection of the larynx. In 1 case, given the initial tumor volume, produced a laryngectomy. In the presence of metastases in regional lymph nodes of the neck in 1 case, made FFIC neck. Reconstructive surgery was performed in 2 patients after resection of the larynx. Complications after surgery was not.

On the 3rd stage of treatment all patients received a course of distance gamma-therapy in the postoperative plan of SOD 46 Gr after laryngectomy and 60-66 Gy after resection depending on the extent of the process according to TNM.

Thus, the entire group was taken in a study of patients managed to hold radical complex treatment.

The proposed method makes it possible to carry out the treatment of patients with locally advanced squamous cell cancer of the larynx and can be used in specialized hospitals (departments of tumors of the head and neck oncological dispensaries).

A method of treating patients with locally advanced squamous cell cancer of the larynx, consisting in carrying out chemotherapy, characterized in that after preliminary catheterization laryngeal artery spend intraarterial chemotherapy by injection of cisplatin in the form of a 6-hour in which usii 80-100 ml 0,0025%solution with 1 to 4-day treatment with a total dose of 100 mg/m 25-fluorouracil in the form of a 3-hour infusion of 20 ml of a 5%solution of 5-th and 7-day treatment with a total dose of 3 g, and after the end of chemotherapy 2-3 weeks after edema side effects in tumor regression of more than 50% perform resection of the larynx, when the regression is less than 50% laryngectomy, 3-4 weeks after complete surgical intervention performed remote radiation therapy at a dose of 2.0 Gy irradiation, the exposure mode 5 times per week and total dose 40-46 Gy when laryngectomy, 60-66 Gy in conservative surgical intervention in depending on the stage of the primary process.



 

Same patents:

FIELD: immunology, biotechnology.

SUBSTANCE: invention relates to variants of nucleic acid construct (NK-construct) encoding of MUC1 antigen based on seven full repeated VNTR-units. Variants include NK-constructs selected from group containing MUC1 based on seven full repeated VNTR-units, MUC1 based on seven full repeated VNTR-units without signal sequence, MUC1 based on seven full repeated VNTR-units without signal sequence, transmembrane and cytoplasm domains, full MUC1 based on seven full repeated VNTR-units without transmembrane and cytoplasm domains, as well as mutants of abovementioned variants, wherein at least one VNTR is mutated to reduce of glycosylation potential. Disclosed are NK-constructs additionally containing epitopes selected from group: FLSFHISNL, NLTISDVSV or NSSLEDPSTDYYQELQRDISE. Also described are variants of expressing plasmide carrying NK-construct represented as DNA, protein having anti-tumor activity, encoded with NK-construct and pharmaceutical composition with anti-tumor activity based on said protein, NK-construct or plasmide. Application of NK-construct and protein for producing of drug for treatment or prevention of MUC-1 expressing tumors; method for therapy by using NK-construct, protein, or plasmide also are disclosed.

EFFECT: NK-constructs with increased anti-tumor activity.

20 cl, 25 dwg, 5 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel derivatives of substituted urea of the formula (I) or their pharmaceutically acceptable salts possessing the retinoid activity, and to pharmaceutical composition and drug based on thereof. In the formula (I) n means a whole number from 0 to 2; X means oxygen atom (O); A-Y means compound of the formula ; R1 and R3 mean independently of one another hydrogen atom, (C1-C6)-alkyl, (C1-C4)-alkylene-(C1-C4)-alkoxy-group, (C1-C4)-alkylenephenyl optionally substituted with halogen atom, (C1-C4)-alkoxy-, (C1-C4)-alkylenebenzyloxy-, (C1-C4)-alkylenehydroxy-group, (C1-C4)-alkylene (monocyclic heteroaryl comprising 5 ring atoms and one or two heteroatoms chosen from atoms N, O or S) optionally substituted with (C1-C6)-alkyl in ring; R2 means hydrogen atom under condition that R1 doesn't mean hydrogen atom or (C1-C6)-alkyl) if R3 means hydrogen atom.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

12 cl, 10 tbl, 3 sch, 27 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to medicinal agent effecting on the immune system. Medicinal preparation comprises 5-amino-2,3-dihydro-1,4-phthalzinedione lithium or potassium salt. Preparations possess the antitumor and antioxidant effect. The developed variants of the medicinal preparation distinct by duration and spectrum of effect and by pharmacokinetic indices and depending on their purity they can be used in oral and intramuscular administration and for other medicinal procedures.

EFFECT: valuable medicinal properties of preparation.

6 cl, 3 tbl, 4 dwg, 12 ex

FIELD: synthesis of biologically active compounds.

SUBSTANCE: invention relates to varioline derivatives of general formula (5a), wherein R1 is selected from halogen and C1-C12-alkyl; R2 is selected from hydrogen and halogen; R3, R4, R5, R6, and R7 represent hydrogen; X1 amino group optionally substituted by C1-C12-alkoxy, benzylamino, C1-C12-alkylsulfinyl, or C1-C12-thioalkyl; X2 amino group, C1-C12-thioalkyl, C1-C12-alkylsulfinyl, or optionally C1-C12-alkoxy-substituted benzylamino; or R1 and R2 pair can be combined into condensed benzene ring system optionally substituted by C1-C12-alkoxy group. Indicated compounds exhibit antitumor activity. Invention further relates to pharmaceutical composition based on these compounds and use of these compounds to prepare drug useful in treatment of cancer. Invention also comprises a method for preparing intermediate varioline compounds. .

EFFECT: expanded synthetic possibilities in heterocyclic compounds area and increased choice of antitumor agents.

16 cl, 107 ex

FIELD: synthesis of biologically active compounds.

SUBSTANCE: invention provides novel urea-substituted imidazoquinoline ethers depicted by general formula I: (1), in which X represents -CHR5- or -CHR5-alkyl group; R1 is selected from radicals: -R4-NR8-CR3-NR5-Z-R6-Alk, -R4-NR8-CR3-NR5-Z-R6-Ph, -R4-NR8-CR3-NR5-Z-R6-furanyl, -R4-NR8-CR3-NR5R-7, phenyl being optionally substituted by one or more substituents selected from methyl, methoxy, methylthio, cyano, hydrogen, dimethylamino, and acetyl; R2 is selected from hydrogen, alkyl, and alkyl-Y-alkyl; R3 represents =O or =S; R4 represents alkyl optionally substituted by one or several O-groups; each of R5 represents C1-C10-alkyl; R6 represents ordinary bond or alkyl; R7 forms cycle together with R5; R4 represents hydrogen, C1-C10-alkyl, or forms morpholine ring together with R8; Y represents -O-; Z ordinary bond, -CO-, or -SO2-; n=0; each of R is independently selected from C1-C10-alkyl, C1-C10-alkoxy, hydroxy, halogen, and trifluoromethyl; or pharmaceutically acceptable salt of forgoing compounds. Described are further compounds of general formula II, intermediates of compounds of general formulae III and IV, pharmaceutical compositions based on compounds I and II, which are immunomodulators for synthesis of cytokines based on compounds I and II, methods of treating viral diseases utilizing compounds I and II, and methods of treating tumor diseases utilizing compounds I and II.

EFFECT: expanded synthetic possibilities in quinoline series and increased choice of therapeutically useful compounds.

25 cl, 4 tbl, 44 ex

FIELD: organic synthesis.

SUBSTANCE: 1-oxo-3-(1H-indol-3-yl)-1,2,3,4-tetrahydroisoquinolines (including their cis- and trans-isomers) are depicted by following general formulae: (1) and (2), in which R1, R2, and R4 independently represent cyclic system substituents selected from hydrogen atom and alkyl; R3 is amino group selected from alkyl, cycloalkyl, and alkyl optionally substituted by aryl, heteroaryl, heterocyclyl, alkoxy, amino, alkylamino, and dialkylamino; R5 and R6 independently represent amino group substituents selected from hydrogen, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkyl, and alkyl optionally substituted by aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, amino, alkylamino, dialkylamino, or arylalkylamino; or R5 and R6, together with nitrogen atom to which they are linked, form optionally substituted aza-heterocycle. Method of preparing compounds 1 consists in reaction of corresponding indol-3-ylmethylamines with homophthalic anhydrides in an organic solvent. Compounds 2 are prepared by treating compounds 1 with thionyl chloride or 1,1'-carbonyldiimidazole to form corresponding derivatives, which are reacted with corresponding amines in an organic solvent. Compounds of invention exhibit proteinkinase inhibiting activities. Combinatory and focused libraries are also provided to reveal leading compounds.

EFFECT: expanded synthetic possibilities in quinoline series and increased choice of proteinkinase inhibitors.

3 cl, 3 tbl, 3 ex

FIELD: synthesis of biologically active compounds.

SUBSTANCE: invention relates to hydroxamate derivatives described by general formula I: , in which R1 represents H or linear C1-C6-alkyl; R2 hydrogen, С110-alkyl optionally substituted by 1-5 constituents selected from hydroxy, amino, hydroxyalkyl; C4-C9-cycloalkyl; aryl; C4-C9-heterocycloalkyl, C4-C9-heterocycloalkylalkyl containing 2 heteroatoms (nitrogen and/or oxygen); C4-C9-cycloalkylalkyl; arylalkyl; heteroarylalkyl containing 1-4 nitrogen atoms as heteroatoms; -(CH2)nC(O)R6, -(CH2)nOC(O)R6, -N(R12)C(O)-W; HONH-C(O)-CH=C(R1)arylalkyl, and (CH2)nR7; R3 and R4, identical or different, independently denote hydrogen, optionally OH-substituted C1-C6-alkyl; C(O)-O-W, or -N(R12)C(O)W; or R3 and R4 together with carbon atom, to which they are linked, represent C=O; or R2 together with carbon atom, to which it is linked, and R3 together with carbon atom, to which it is linked, can form C4-C9-heterocycloalkyl containing 2 nitrogen atoms as heteroatoms; or mixed aryl or non-aryl polyheterocyclic ring; R5 is selected from hydrogen; C1-C6-alkyl; C4-C9-cycloalkyl; C(O)-W; aryl optionally substituted by 1-2 constituents selected from halogen and hydroxyalkyl; heteroaryl containing nitrogen as heteroatom; arylalkyl; aromatic polycycle; polyheteroaryl containing 1-2 nitrogen atoms as heteroatoms and optionally substituted by 1-2 substituents selected from hydroxyalkyl, halogen, alkyl, and aryl; mixed aryl-nonaryl polyheterocycle containing nitrogen or oxygen atom as heteroatom and optionally substituted by groups -N-OH, =N-OH; n, n1, n2, and n3, identical or different, are independently selected from within a range of 0-6; X and Y, identical or different, are independently selected from hydrogen, halogen, and nitro group; or pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition showing inhibitory activity toward hydroxamate derivative of general formula I in combination with one or several pharmaceutically acceptable carriers. Hydroxamate derivative of general formula I are also appropriate for treating proliferative disease and regulating p21 promoter.

EFFECT: enabled use of hydroxamate derivatives as deacetylase inhibitors.

42 cl, 6 tbl, 272 ex

FIELD: medicine, oncology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition and its using in cancer treatment. Invention relates to polyphenol-containing pharmaceutical compositions wherein the concentration of polyphenols provides the effectiveness in cancer treatment. Proposed compositions are used as an agent for prophylaxis and treatment of cancer, and these compositions comprise ascorbic acid, lysine, proline and at least one polyphenolic compound chosen from group consisting of epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin and catechin. The claimed polyphenol-base pharmaceutical compositions are able to block proliferation of cancer cells and metastazing process effectively.

EFFECT: valuable medicinal properties of composition.

19 cl, 14 dwg, 10 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: method involves applying alternating sinusoid magnetic field for 8 days in interrupted mode with sending and pause duration equal to 2 s, inductance of 60 mTesla units and frequency of 50 Hz during 5-10 min. Antitumor chemopreparations combined with autoblood are introduced at the first and eighth treatment day in intravenous and drip feed mode. Blood is taken from peripheral vein into two bottles containing blood preservative in the amount of 100 ml in each. 30 mg/m2 of Doxorubicine is introduced into the first bottle, 500 mg/m2 of 5-fluorouracyl and 600 mg/m2 of cyclophosphane into the second one. Then both bottles are incubated and the contents of the first bottle is injected, and then the content of the second one. Surgical removal of relapse is carried out two weeks later after the last antitumor preparation introduction.

EFFECT: avoided adverse toxic side effects; no additional medical preparations consumption; completely eliminated lesion focus.

2 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing bio-organic animal preparation in advance during 4 days at daily intramuscular dose of 0.3 per 100 g of animal mass, before introducing cancerogenic agent. Then, the cancerogenic agent injections are started and continued during 30 days.

EFFECT: increased tissular resistance, antitumor immunity and phagocytic macrophage activity.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves arranging active positions of walking source in known way. Dosimetric plan of walking source iridium-192 has fourteen active positions uniformly distributed in regular intervals in pairs 7.5 mm one from another, the source having step size of 2.5 mm, in single ring applicator "Ring Applicator Sets" having ring diameter of 30 mm and active length of 80 mm, of Microselectron HDR device.

EFFECT: reduced malignant tumor recurrence risk.

1 tbl

FIELD: medicine, oncology.

SUBSTANCE: one should carry out surgical interference , distance gamma-therapy and hormonotherapy with aromatase inhibitors. Moreover, after surgical interference it is important to determine the level of aromatase in remote tumor, at its value being 7fM androstenedione/mg protein/h and more, despite the receptor status one should prescribe hormonotherapy with aromatase inhibitor - anastrosol - at the dosage of 1 mg/d once for 6 mo running on finishing distance gamma-therapy. Such a complex therapy due to taking into account the threshold value of aromatase level in tumor enables to decrease the frequency of local relapses considerably during the first 2 yr of life after therapy conducted, in case of minimal quantity of therapeutic complications.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out 5-10 sessions of general magnetotherapy beginning from 3-rd day after surgical intervention in static mode: magnetic field rotation frequency is equal to 100 Hz, magnetic field intensity of 30 oersted, magnetic field shape is sinusoid half-cycle, raising time being equal to 30 s, time of recession 30 s; the number of procedures is equal to 15. Then, remote radiation therapy is administered 4 weeks later after surgical intervention. The treatment is applied to removed kidney bed and lymphatic collectors in single stage in classical fractioning mode at a doze of 2 Gy 5 times a week within 5 weeks up to reach total doze of 50 Gy with general magnetotherapy being concurrently applied in 1 session per day mode, the number of procedures being equal to 25. The first biotherapy course with recombinant human alpha tumor necrosis factor (TNF-α) is given at a dose of 2 mln units 2 weeks later after the radiation therapy being done. Total З biotherapy courses are to be given with 21 days long pause available between the courses.

EFFECT: enhanced effectiveness of treatment; reduced risk of postoperative complications; increased immune activity.

FIELD: medicine, oncology.

SUBSTANCE: method involves carrying out lumbal puncture to a patient in post-operative period, subarachnoid space is catheterized, and 5 ml of liquor is removed followed by incubation of liquor with nimustine taken in the dose 5 mg in vitro at temperature 38°C for 30 min, and liquor is administrated into subarachnoid space through catheter. Procedure is carried out 2 times with interval for 7 days. Since the second day after onset of this procedure distant gamma-therapy on bed of removed tumor is carried out up to the total focus dose 60 Gr. Method provides stable remission, decreasing toxicity of chemopreparation, frequency of adverse by-side effects and significant reducing the cost of chemotherapy. Invention can be used in carrying out the adjuvant chemoradiation therapy of brain malignant glial tumors.

EFFECT: improved method of chemoradiation therapy, enhanced effectiveness of method.

1 ex

FIELD: medicine, radiation medicine.

SUBSTANCE: it has been suggested to apply lactoferrin as a curative preparation in case of acute radiation disease. Lactoferrin should be applied in the experiment at reproducing madullary form of acute radiation disease. Subcutaneous injection of lactoferrin in physiological solution at the dosage of 300 mcg/kg is accompanied with statistically significant increase of lymphocytes and neutrophils in peripheral blood that provides 100%-survival rate of irradiated animals in experimental group.

EFFECT: higher efficiency of therapy.

1 ex, 2 tbl

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with adjuvant chemoradiation therapy of malignant cerebral meningiomas. In postsurgical period it is necessary to carry out lumbar puncture, catheterize subarachnoid space, sample 5 ml liquor, incubate liquor with cisplatin at the quantity of 0.1 mg in vitro at 38°C for 30 min to introduce it through a catheter into subarachnoid space. The procedure should be carried out twice at a 7-d-long interval, since the 2nd d of the beginning of this procedure it is necessary to conduct distance gamma-therapy at the bottom of removed tumor daily for 20 d up to total focal dosage being 60 Gy. The innovation enables to achieve stable remission, decrease toxicity of chemopreparation and frequency of side effects at considerable decrease of its cost price.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, oncogynecology.

SUBSTANCE: it is necessary to carry out expanded uterine extirpation and intrasurgical radiation therapy (ISRT). In women of reproductive age at squamous cell forms of uterine cervix cancer before the stage of expanded uterine extirpation one should fulfill ovarian transposition by fixing them in the upper departments of lateral canals of abdominal cavity to provide their functional safety and integrity of vascular peduncle. On finishing the stage of expanded uterine extirpation it is important to form the field of irradiation that includes vaginal stump and perivaginal fiber by restricting the organs of small pelvis and abdominal cavity against irradiation region. Irradiation should be carried out due to distance technique by providing the dosage of 15 Gy in the preset area. On finishing the ISRT seance it is necessary to conduct peritonization of small pelvis. The innovation enables to decrease the frequency of postsurgical complications that take place while ISRT procedure.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: medicine, oncology, radiology.

SUBSTANCE: the suggested thermochemoradiation treatment should be fulfilled in three stages at intervals between each of them being 10-14 d: during the 1st stage it is necessary to carry out distance gamma-therapy daily at fractionating the dosage during 1-3 d per 4 Gy, then during 4-22 d per 2 Gy up to TFD being 50 isoGy, radiosensitization with 5-fluorouracil daily at the dosage of 125 mg intravenously at flow-type technique 30 min before the séance of radiation treatment and local thermotherapy with transrectal sensor once/2 d, every other day, just before gamma-therapy; during the 2nd stage it is necessary to conduct radiosensitization and local thermotherapy similarly, as it was during the first stage, as for irradiation it should be carried out as intracavitary gamma-therapy daily per 3 Gy up to TFD being 18-24 Gy; during the 3d stage one should fulfill radiosensitization with fluorouracil as during the first and second stages and carry out distance gamma-therapy daily per 2 Gy so that TFD from all three stages should achieve 74 isoGy.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with complex therapy of mammary gland cancer at T1-2NO-1MO. The method includes chemo- and radiation therapy and operation procedure. Moreover, in post-surgical period, before the onset of radiation therapy course it is necessary to sample 200 ml patient's blood and due to centrifuging technique isolate autoplasma. One should place 20 ml autoplasma and chemopreparations into the first vial, into the second vial - remained blood cells and autoplasma. Vials should be separately incubated for 40 min at 37° C, then during the first day of radiation therapy before the onset of the seance one should introduce the half of autoplasma volume incubated with chemopreparations from the first vial into the ducts of operated mammary gland, as for the remained part of autoplasma incubated with chemopreparations, from the first vial it should be introduced into the site of surgical withdrawal of drainage tube. Blood incubated with chemopreparations from the second vial should be reinfused intravenously by drops. The innovation is of low toxicity and enables to carry out complex organ-saving therapy in short terms, decrease the frequency of local relapses and remote metastases, the number of radiation reactions and complications.

EFFECT: higher efficiency.

2 ex

FIELD: methods and devices for treatment of oncology patients using sources of ionizing radiation, namely, technology of pre-irradiation preparation and irradiation during intracavitary and interstitial radiotherapy.

SUBSTANCE: method for pre-irradiation preparation and irradiation includes positioning the patient on treatment-diagnostics table, inserting into cavity to be irradiated of hollow applicators with imitators of ionizing radiation sources, controlling position thereof relatively to target being irradiated with usage of x-ray television device, building of dosimetric plane and irradiation, while applicators inserted into cavity being irradiated are connected to treatment-diagnostics table, x-ray radiography is performed with output of image onto monitor of viewing station of x-ray television device, image via the interface is transported into planning system, dosimetric plane of irradiation is computed, which is then exported into system for controlling device and irradiation procedure is performed. Treatment-diagnostics table has frame, two supporting posts with overhung table top mounted on them, consisting of a pelvic-dorsal and two extending leg sections, connected to pelvic-dorsal section by means of twin joints. For connection of applicator table is provided with mounting pillar.

EFFECT: possible irradiation directly near apparatus without moving the patient during x-ray control of position of applicators and, therefore, increased quality of radiotherapy and therapeutic efficiency, decreased duration of pre-irradiation preparation.

2 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing flexible tube into the abdominal cavity with injection needle being attached without cannula to one of its ends and needle cannula being attached to the other end. Fluoroplastic tube is caught by means of manipulator on the needle boundary. Organ is punctured under vision control. Drug solution is introduced into organ parenchyma without removing the manipulator.

EFFECT: reduced risk of traumatic complications; high accuracy of drug target delivery.

1 dwg

Up!